ProSomnus Sleep Technologies is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes.

ProSomnus Sleep Technologies is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices, sophisticated and custom mouth retainers, are engineered to precisely track the treatment plan and anatomy for each patient. ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations, according to the company. In February, for example, the company reported a successful pilot study validation of a next generation remote patient monitoring device for Obstructive Sleep Apnea.

“ProSomnus is a healthy, growing, thriving business that is also trying to do good for the world by treating this poorly managed, underserved, and highly prevalent disease called obstructive sleep apnea,” says Len Liptak, CEO, Director, and Founder. “Our mission is for our devices to enable the best treatment and disease management for the one billion people worldwide with Obstructive Sleep Apnea. Every one of our devices is customized to precisely fit the unique airway anatomy for each patient. Clinical studies have linked our personalization with more effective, more comfortable, and more efficient procedures for patients and providers.

The company’s flagship device is called the ProSomnus EVO Sleep and Snore Device. It is the only device in sleep medicine made entirely from verified Medical Grade Class VI material. Medical Grade Class VI is the highest designation of biocompatible material as rated by US Pharmacopeia. “CPAPs, CPAP Cleaning devices, and other treatments for Obstructive Sleep Apnea have been plagued by FDA recalls, safety concerns, adverse events, and side effects,” according to Liptak. “Our EVO device is engineered for safety.”

ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE, and many government-sponsored healthcare plans around the world. Liptak notes that one third of married couples report having a sleep divorce due to snoring and sleep apnea. “Patients who have sleep apnea have significantly higher rates of morbidity and mortality than those without sleep apnea. So, if you snore, fall asleep while watching TV, get drowsy driving your vehicle, or stop breathing at night, please tell your doctor.”

The Hacienda location, which serves an estimated 107 employees, is the global headquarters for ProSomnus. It also has locations in Germany to support its business in Europe. In 2023, ProSomnus moved its global headquarters within Hacienda, in part to keep the benefits of its central location.

“The intersection of 680 and 580 plus BART and buses make it easy for our employees, who reside all over the East Bay, to get to and from work every day,” says Liptak. “We also needed a facility that met certain requirements for our medical device manufacturing system.”

For more information about ProSomnus, please visit www.prosomnus.com, www.linkedin.com/company/prosomnus-sleep-technologies/, www.facebook.com/ProSomnusSleepTechnologies, or www.instagram.com/prosomnussleeptechnologies.